Jaguar Health, Inc. (JAGX)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenue, net | 2,979 | 2,214 | 3,108 | 2,721 |
| Sales and marketing | 2,467 | 2,493 | 2,010 | 1,524 |
| Research and development | 3,265 | 3,730 | 4,043 | 3,653 |
| General and administrative | 4,727 | 4,897 | 3,776 | 4,314 |
| Cost of product revenue | 527 | 515 | 541 | 427 |
| Total operating expenses | 10,986 | 11,635 | 10,370 | 9,918 |
| Loss from operations | -8,007 | -9,421 | -7,262 | -7,197 |
| Interest income (expense) | -15 | -56 | -162 | -108 |
| Gain (loss) on extinguishment of debt | -1,822 | - | - | - |
| Changes in fair value of freestanding and hybrid financial instruments designated at fair value option | 1,068 | 1,343 | 3,089 | 1,810 |
| Other income (expense) | 322 | 112 | 168 | -729 |
| Loss before income tax expense | -10,560 | -10,596 | -10,021 | -9,628 |
| Net loss before equity in net loss of joint venture | - | -10,596 | - | - |
| Net loss | -10,560 | -10,596 | -10,021 | -9,492 |
| Net income (loss) attributable to noncontrolling interest | - | - | - | -136 |
| Net income (loss) available to common stockholders, basic | - | - | - | -9,492 |
| Net loss per share, basic | -10.26 | -16.7 | -1.05 | -4.04 |
| Net loss per share, diluted | -10.26 | -16.7 | -1.05 | -4.04 |
| Weighted-average common stock outstanding, basic | 1,014,783 | 626,644 | 9,370,136 | 2,349,431 |
| Weighted-average common stock outstanding, diluted | 1,014,783 | 626,644 | 9,370,136 | 2,349,431 |